All News

Albuminuria (uACR) flags early vascular damage linking chronic kidney disease and cardiovascular risk.

Independent pharmacies produce some of health care’s most valuable data, yet much of the profit and power they create bypasses the pharmacies entirely.

A new 2026 American Heart Association study shows COVID-19 infection sharply raises heart attack risk, whereas vaccination appears safe—key guidance for patient counseling.

Ahead of the Sports Pharmacy Summit, a pharmacist weighs GLP-1s for athlete weight management benefits.

Pharmacists play a key role in modern obesity care through education, access support, and collaboration.

Long-acting HIV injections and twice-yearly PrEP reshape care, while pharmacists tackle stigma, insurance hurdles, and adherence to close access gaps.

Clinical pharmacists reshape PBMs with medication optimization, cutting drug spend and improving outcomes through smarter, safer prescribing.

Swapping 30 minutes of teen sedentary time for vigorous activity or extra sleep cuts insulin resistance by 15%, aiding type 2 diabetes (T2D) prevention.

Joseph Saseen, PharmD, breaks down how the new PREVENT ASCVD calculator improves on its predecessor and what the expanded LDL-C goal framework means for treatment decisions in pharmacy practice.

From bispecifics to real-world evidence, Amy Seung previews the science, community, and advocacy opportunities defining this year's meeting.

Deucravacitinib, a selective TYK2 inhibitor, demonstrates efficacy comparable to biologics while offering meaningful improvements in symptoms and quality of life for patients with psoriatic arthritis.

Craig Beavers discusses how mavacamten's established long-term safety data strengthen shared decision-making conversations, and outlines best practices for multidisciplinary collaboration when implementing cardiac myosin inhibitor therapy in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Case reports show that alternative agents, including phenytoin, have been successful in resolving digoxin-induced arrhythmias.

Emerging therapies, AI, and patient-centered approaches are reshaping cardiovascular pharmacy.

CDK4/6 inhibitor therapies must by tailored by comorbidities, interactions, cost, and coordinated labs with pharmacist expertise to support high-risk patients.

Nutrition coaching and pharmacist support boost medication adherence, tackle access barriers, and strengthen chronic disease routines.

Craig Beavers explains how mavacamten's REMS program and its clearly defined echo-based monitoring protocols create a unique opportunity for pharmacists to take an active role in managing patients with obstructive hypertrophic cardiomyopathy (oHCM).

This week's episode covers the court ruling halting RFK Jr.'s childhood vaccine schedule changes, the FDA's RSV vaccine approval for adults aged 18–49, pharmacist-led GLP-1 optimization strategies, and new gabapentin data in SUD treatment settings.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Sharon Nachman, MD, equips pharmacists with clear, evidence-based talking points to address vaccine hesitancy and help parents navigate the confusion created by the legal battle over childhood immunization schedules.

Community pharmacists boost asthma control by improving adherence, inhaler technique, and access—cutting exacerbations and emergency department visits.

Learn why uACR screening flags early vascular damage linking chronic kidney disease and cardiovascular health.

Artificial intelligence is emerging as a vital tool for pharmacists in cardiovascular care—supporting clinical decisions, patient education, and adherence while maintaining guideline alignment.

The FDA approval of the Wegovy pill offers a new, effective GLP-1 option for weight management, with pharmacists playing a key role in patient counseling and adherence support.

The expanded indication is supported by findings from the phase 3 TRANSCEND clinical trial.